December 10th- ASH 2025 Spotlight: Sustained MRD as a Transformative Endpoint in Transplant-Ineligible Myeloma- Insights from the BENEFIT Phase 3 Study

December 9th- ASH 2025 Spotlight: inMMyCAR: First-in-Human In Vivo CAR-T for Relapsed/Refractory Myeloma

December 9th- ASH 2025 Spotlight: MajesTEC-3: A Landmark Phase 3 Trial in Relapsed/Refractory Myeloma

December 9th- ASH 2025 Spotlight: Real-World Symptom Improvement With Belumosudil in Chronic GVHD

December 9th- ASH 2025 Spotlight: Response Dynamics to Belumosudil in Chronic GVHD

December 8th- ASH 2025 Highlight: MaaT013 in Steroid- and Ruxolitinib-Refractory Acute GI GVHD

December 8th- ASH 2025 Highlight: What’s New in Myeloid Malignancies at ASH 2025?

December 7th- ASH 2025 Spotlight: The Rise of Golcadomide

December 7th- ASH25 Highlights: What’s New in Lymphoid Malignancies at #ASH25?

December 6th- ASH 2025 Spotlight: The VERIFY Trial